ASX:ALT

Stock Analysis Report

Executive Summary

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States.

Snowflake

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Analytica's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

33.3%

ALT

4.9%

AU Medical Equipment

0.9%

AU Market


1 Year Return

-20.0%

ALT

46.9%

AU Medical Equipment

16.3%

AU Market

Return vs Industry: ALT underperformed the Australian Medical Equipment industry which returned 46.9% over the past year.

Return vs Market: ALT underperformed the Australian Market which returned 16.3% over the past year.


Shareholder returns

ALTIndustryMarket
7 Day33.3%4.9%0.9%
30 Day0%5.0%1.4%
90 Day0%13.4%6.0%
1 Year-20.0%-20.0%49.3%46.9%23.0%16.3%
3 Year-33.3%-33.3%69.5%62.0%41.6%22.3%
5 Year-84.1%-85.2%159.3%138.5%57.7%22.5%

Price Volatility Vs. Market

How volatile is Analytica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Analytica undervalued compared to its fair value and its price relative to the market?

8.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALT is overvalued based on its PB Ratio (8.5x) compared to the AU Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Analytica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Analytica performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALT has a high level of non-cash earnings.

Growing Profit Margin: ALT's current net profit margins (-253.2%) are lower than last year (-216.3%).


Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, but has reduced losses over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.5%).


Return on Equity

High ROE: ALT has a negative Return on Equity (-123.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Analytica's financial position?


Financial Position Analysis

Short Term Liabilities: ALT's short term assets (A$2.0M) exceeds its short term liabilities (A$562.1K)

Long Term Liabilities: ALT's short term assets (2.0M) exceeds its long term liabilities (9.4K)


Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.


Balance Sheet

Inventory Level: ALT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ALT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALT has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.6% each year.


Next Steps

Dividend

What is Analytica's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Analytica's salary, the management and board of directors tenure and is there insider trading?

7.7yrs

Average board tenure


CEO

Geoff Daly 0

5.8yrs

Tenure

AU$273,750

Compensation

Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Opera ...


CEO Compensation Analysis

Compensation vs Market: Geoff's total compensation ($USD186.45K) is about average for companies of similar size in the Australian market ($USD255.13K).

Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

7.7yrs

Average Tenure

Experienced Board: ALT's board of directors are considered experienced (7.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$514,06507 Jun 19
Michael Monsour
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares102,632,612
Max PriceAU$0.005
BuyAU$77,05207 Jun 19
Ross Mangelsdorf
EntityIndividual
Role
Member of the Board of Directors
CFO & Executive Director
Shares15,414,040
Max PriceAU$0.005

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.


Management Team

  • Bryan Dulhunty

    Company Secretary

    • Tenure: 7.1yrs
    • Compensation: AU$19.08k
  • Michael Monsour

    Executive Chairman

    • Tenure: 15.4yrs
    • Compensation: AU$82.13k
  • Geoff Daly

    Chief Executive Officer

    • Tenure: 5.8yrs
    • Compensation: AU$273.75k
  • Ross Mangelsdorf

    CFO & Executive Director

    • Tenure: 11.1yrs
    • Compensation: AU$199.22k
  • Chelsea Cornelius

    Product Development & Operations Manager

    • Tenure: 0yrs
  • Megan Henken

    Vice President of Global Marketing

    • Tenure: 0yrs

Board Members

  • Peter Corr (71yo)

    Non-Executive Director

    • Tenure: 2.5yrs
    • Compensation: AU$61.25k
  • Michael Monsour

    Executive Chairman

    • Tenure: 15.4yrs
    • Compensation: AU$82.13k
  • Ross Mangelsdorf

    CFO & Executive Director

    • Tenure: 11.1yrs
    • Compensation: AU$199.22k
  • Thomas Lönngren

    Non-Executive Director

    • Tenure: 4.3yrs
    • Compensation: AU$54.75k

Company Information

Analytica Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Analytica Limited
  • Ticker: ALT
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$14.078m
  • Shares outstanding: 3.52b
  • Website: https://www.analyticamedical.com

Location

  • Analytica Limited
  • 320 Adelaide Street
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2000
ALTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2000

Biography

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company’s lead product is PeriCoach system, an e-health treatment system for w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/17 10:32
End of Day Share Price2019/11/14 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.